ION224 for Non-alcoholic Fatty Liver Disease
Trial Summary
Will I have to stop taking my current medications?
You may need to stop taking certain medications, especially if they are associated with non-alcoholic fatty liver disease or if you are not on a stable dose. It's best to discuss your specific medications with the trial team to see if any changes are needed.
What makes the drug ION224 unique for treating non-alcoholic fatty liver disease?
What is the purpose of this trial?
This trial tests if ION224 injections can help patients with NASH by reducing liver fat and improving liver health. The study will monitor changes in liver condition using imaging and blood tests over several months.
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ION224 or placebo by subcutaneous injection every 4 weeks for up to 49 weeks
Post-Treatment
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- ION224
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ionis Pharmaceuticals, Inc.
Lead Sponsor
Dr. Brett P. Monia
Ionis Pharmaceuticals, Inc.
Chief Executive Officer since 2020
PhD in Pharmacology from the University of Pennsylvania, BSc in Molecular Biology and Analytical Chemistry from Stockton State College
Dr. Eric Bastings
Ionis Pharmaceuticals, Inc.
Chief Medical Officer
MD